Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Maintain Funding for COVID Pill beyond April: Academic Societies to Govt
February 13, 2024
- Japan Approves Jardiance for CKD, Label Expansion for Opdivo and More
February 13, 2024
- Japan to Allow Submissions without Japanese Data If All Requirements Met
February 9, 2024
- FPMAJ Supports Generic Industry Consortia Concept but Frets Antitrust Issues
February 9, 2024
- Health Minister Admits Antitrust Challenge in Generic Industry Revamp
February 9, 2024
- Takeda’s Acquired Hemophilia A Drug Up for Panel Review on February 22
February 9, 2024
- New Govt Forum Moots US-Level Trial Environment, Priority Review Vouchers
February 9, 2024
- Generic Panel to Issue Report in Spring-Summer to Drive Manufacturing Efficiency towards Stable Supplies: Official
February 8, 2024
- Japan to Revamp Scheme for Drug Maker’s Reporting of Supply Concerns in April
February 7, 2024
- Legal Changes on Horizon for GMP Inspection Authorities, Other Regulation Panel Topics?
February 7, 2024
- Govt Eyes Boosted Manpower at AMED towards Next 5-Year Plan from FY2025
February 7, 2024
- AMED Needs More Manpower to Fulfill Its Role as Funding Agency: President
February 6, 2024
- Opdivo, Olumiant, Dupixent Now in Line for Label Expansions
February 6, 2024
- CSL’s Hemophilia Gene Therapy to Get Orphan Tag in Japan
February 6, 2024
- Truvada Clears Preliminary Review for PrEP Use, but Coverage Not Granted
February 6, 2024
- Generic Firms Required to Disclose Supply Info from June after Pilot Rollout of Company Indicators
February 5, 2024
- Will Truvada Win Health Coverage as Japan’s First Drug for HIV Prevention?
February 5, 2024
- MHLW to Kick Off Debates on PMD Act Amendment on Feb. 9
February 5, 2024
- Physician Meals Costs, Seminar Expenses Newly Subject to Disclosure under Clinical Trials Act from April
February 2, 2024
- Annual Drug Price Revisions Based on 4-Minister Agreement: Japan PM
February 2, 2024
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…